Effects of intermittent fasting on HbA1c and weight in insulin versus oral hypoglycemic therapy-treated patients with type 2 diabetes mellitus: a systematic review and meta-analysis
Al Qudah J, Beni ND, Ibrahim N, Khader S, Dempsey L, Butler AE
Frontiers in nutrition · 1 cita
Cómo se estudió
- Diseño
- Revisión sistemática (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
Según la declaración de financiación del texto completo.
Publicación
- Publicado
- 2026-01-30 · Front Nutr · vol. 13 · pág. 1699384
- Editorial
- Frontiers Media
- Citado
- 3 citas · más que el 95% de estudios similares · 5.7× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 28 trabajos
- Acceso
- Acceso abierto (revista) · CC-BY
- Áreas de investigación
- Dietary Effects on Health · Diabetes Management and Research · Diet and metabolism studies
- Palabras clave
- intermittent fasting, type 2 diabetes, HbA1c, glycemic control, body weight, insulin therapy, oral antidiabetic drugs, time-restricted feeding, alternate-day fasting, fasting-mimicking diet, Ramadan fasting, weight loss
6 autores
- Jana Al Qudah🇧🇭Royal College of Surgeons in Ireland - Bahrain
- Newsha Davoudian Beni🇧🇭Royal College of Surgeons in Ireland - Bahrain
- Nooran Ibrahim🇧🇭Royal College of Surgeons in Ireland - Bahrain
- Salma Khader🇧🇭Royal College of Surgeons in Ireland - Bahrain
- Laura Dempsey🇮🇪Royal College of Surgeons in Ireland
- Alexandra E. Butler🇧🇭 · autor de correspondenciaRoyal College of Surgeons in Ireland - Bahrain
Resumen
El texto original del estudio, en el idioma en que se publicó.
Aim
Intermittent fasting (IF) has emerged as a beneficial dietary strategy for managing type 2 diabetes mellitus (T2DM), with improvements in certain indicators of body composition and cardiometabolic health. However, limited research compares the different effects of IF in oral hypoglycemic agents (OHAs) versus insulin-treated patients.
Methods
A comprehensive search was performed across PubMed, Scopus, and Cochrane Library (January 2010-January 2025). Randomized controlled trials (RCTs) involving adults (>18-years) with T2DM undergoing IF, time-restricted feeding (TRF), alternate-day fasting (ARF), fasting-mimicking diets (FMD), and Ramadan fasting were included.
Results
In total, 12 studies (n = 1,441 participants) met the inclusion criteria. IF improved glycemic control in both groups, with HbA1c reductions of 0.54% in OHA-users and 2.8% in insulin-users. In the meta-analysis of four eligible trials (n = 280), IF produced a significant pooled reduction in HbA1c (-1.85, 95% CI: -2.86 to -0.84), despite substantial heterogeneity (I2 = 98.1%). In contrast, IF did not produce a significant change in body weight (-1.45 kg, 95% CI: -5.51 to 2.61; I2 = 96.7%). Most studies reported weight loss, with an average body mass index (BMI) reduction of 1.53 kg/m2 in OHA users. Among insulin-users, one study reported a significant reduction in weight for the IF group (-4.77 ± 4.99 kg, p < 0.001).
Conclusion
IF represents an effective adjuvant therapeutic strategy in T2DM and could be widely employed in clinical practice.
Systematic review registration
Identifier CRD42025650065, https://www.crd.york.ac.uk/PROSPERO/view/CRD42025650065.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.